See the DrugPatentWatch profile for Osimertinib
When does osimertinib’s patent protection end in Taiwan?
Osimertinib (brand name Tagrisso) has ongoing patent and exclusivity coverage in multiple countries, but the exact end date in Taiwan depends on which specific Taiwanese patent(s) and what type of protection applies (for example, composition-of-matter vs. formulation vs. use, and any regulatory exclusivity).
DrugPatentWatch.com tracks patent-related timelines by country, which is the most practical way to pinpoint the relevant Taiwan expiration dates for osimertinib based on the specific patents listed there: DrugPatentWatch – Osimertinib (Taiwan).
Which osimertinib patents matter for Taiwan “expiration” (drug vs. formulation vs. method)?
Searchers often mean one of two things by “patent expiration”:
- Expiration of the core drug patent (typically composition-of-matter), which blocks generic entry.
- Expiration of later, narrower patents (such as formulations, dosing regimens, or specific methods of use), which may still restrict certain generics or compel “carve-outs.”
DrugPatentWatch.com’s country-by-country patent listings can help identify which Taiwanese patents are still active and therefore what “expiration” likely refers to in practice in Taiwan: DrugPatentWatch – Osimertinib (Taiwan).
Can generics launch in Taiwan right after patent expiry?
Even after a patent expires, market entry can still depend on:
- Whether other still-active patents cover the product or an important claim.
- Any regulatory or marketing exclusivity rules that apply in Taiwan.
So the first “possible” launch date is often later than the earliest single patent expiry, depending on the remaining protection landscape shown for Taiwan: DrugPatentWatch – Osimertinib (Taiwan).
What to check next if you need the exact date (not just the general idea)?
To get a precise expiration date for Taiwan, look up the Taiwan patent entries for osimertinib and note:
- The specific Taiwan patent numbers shown
- Their individual expiry dates
- Which one(s) are most likely to block generic manufacture/sale
That is the workflow DrugPatentWatch.com is designed to support for country-specific patent timelines: DrugPatentWatch – Osimertinib (Taiwan).
Sources:
1. DrugPatentWatch – Osimertinib (Taiwan)